Covered recipient · General Payments record
CHARLES MONTANO
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$178,802.83
372 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $94,558.00 | 32 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $64,381.00 | 25 |
| Travel and Lodging | $11,869.03 | 32 |
| Food and Beverage | $7,993.60 | 282 |
| Education | $1.20 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 4 of 8; records 151–200 of 372 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CHARLES MONTANO
NPI 1487673208 · CMS profile ID 294754
Allopathic & Osteopathic Physicians / Internal Medicine
CROMWELL, CT
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 8; records 151–200 of 372 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1487673208?year=2024&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CHARLES MONTANO, NPI 1487673208, CMS profile ID 294754. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 8; records 151–200 of 372 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487673208?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). CHARLES MONTANO, NPI 1487673208, CMS profile ID 294754. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 8; records 151–200 of 372 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487673208?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- CHARLES MONTANO, NPI 1487673208, CMS profile ID 294754, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 8; records 151–200 of 372 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1487673208?year=2024&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
372 matching records · $178,802.83 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 372.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Corium, LLC | $6.23 | 08/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1100147435 | CMS |
| Corium, LLC | $6.76 | 08/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1100148501 | CMS |
| Merck Sharp & Dohme LLC | $17.31 | 07/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141954596 | CMS |
| Otsuka America Pharmaceutical, Inc. | $6.45 | 07/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118944899 | CMS |
| ABBVIE INC. | $5.11 | 07/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105056972 | CMS |
| Axsome Therapeutics, Inc. | $73.30 | 07/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148271031 | CMS |
| Axsome Therapeutics, Inc. | $3,413.00 | 07/17/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148271033 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5.85 | 07/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143280926 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.25 | 07/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1153516732 | CMS |
| ABBVIE INC. | $6.08 | 07/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105056966 | CMS |
| ABBVIE INC. | $3.70 | 07/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105056968 | CMS |
| ABBVIE INC. | $6.07 | 07/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105056970 | CMS |
| Corium, LLC | $28.72 | 07/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1100198710 | CMS |
| Astellas Pharma US Inc | $16.00 | 07/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139280770 | CMS |
| EVOKE PHARMA, INC. | $9.95 | 07/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127777309 | CMS |
| ABBVIE INC. | $3.47 | 07/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105056964 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,160.00 | 07/08/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143280919 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.70 | 07/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143280923 | CMS |
| Corium, LLC | $28.98 | 07/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1100199172 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $7.96 | 07/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143280916 | CMS |
| Otsuka America Pharmaceutical, Inc. | $14.78 | 07/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118944897 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $18.23 | 07/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137637702 | CMS |
| Corium, LLC | $8.13 | 06/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1100151515 | CMS |
| Corium, LLC | $15.86 | 06/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1100166289 | CMS |
| Lundbeck LLC | $21.45 | 06/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145947684 | CMS |
| Alkermes, Inc. | $8.03 | 06/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120557221 | CMS |
| Lilly USA, LLC | $18.77 | 06/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136093757 | CMS |
| Alkermes, Inc. | $5.91 | 06/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120557219 | CMS |
| Corium, LLC | $2,800.00 | 06/25/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1100220953 | CMS |
| ABBVIE INC. | $630.00 | 06/21/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105056962 | CMS |
| ABBVIE INC. | $8.89 | 06/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105056960 | CMS |
| EVOKE PHARMA, INC. | $5.74 | 06/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127777101 | CMS |
| Otsuka America Pharmaceutical, Inc. | $2,106.00 | 06/20/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118944895 | CMS |
| ABBVIE INC. | $11.92 | 06/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105056958 | CMS |
| Axsome Therapeutics, Inc. | $2,363.00 | 06/18/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148271027 | CMS |
| Axsome Therapeutics, Inc. | $125.00 | 06/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148271029 | CMS |
| Otsuka America Pharmaceutical, Inc. | $2,106.00 | 06/14/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118944893 | CMS |
| Alkermes, Inc. | $5.37 | 06/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120557217 | CMS |
| Corium, LLC | $800.00 | 06/13/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1100221195 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.83 | 06/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143280912 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5.70 | 06/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143280908 | CMS |
| Otsuka America Pharmaceutical, Inc. | $18.42 | 06/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118944891 | CMS |
| Amgen Inc. | $13.72 | 06/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117331264 | CMS |
| Corium, LLC | $7.25 | 06/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1100128120 | CMS |
| Otsuka America Pharmaceutical, Inc. | $124.99 | 06/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118944889 | CMS |
| Corium, LLC | $15.59 | 06/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1100111326 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.94 | 06/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143280897 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.36 | 06/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143280901 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $27.15 | 06/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143280904 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $135.75 | 06/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143280875 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,612.49 | 7 |
| PY2025 | Principal investigator | $291,920.04 | 119 |
| PY2024 | Recipient | $8,649.00 | 2 |
| PY2024 | Principal investigator | $803,962.75 | 106 |
| PY2023 | Recipient | $49,421.36 | 10 |
| PY2023 | Principal investigator | $191,996.02 | 31 |
| PY2022 | Principal investigator | $272,984.79 | 71 |
| PY2021 | Recipient | $35,295.40 | 7 |
| PY2021 | Principal investigator | $132,283.19 | 47 |
| PY2020 | Recipient | $3,304.21 | 19 |
| PY2020 | Principal investigator | $112,711.56 | 29 |
| PY2019 | Recipient | $33,476.95 | 5 |
| PY2019 | Principal investigator | $39,567.22 | 17 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
126 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $3,445.60 | 12/31/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects with Generalized Anxiety Disorder who have had an Inadequate Response to Antidepressant Therapies | No dispute reported | 06/30/2026 | 1202534053 |
| Principal investigator 1 | ABBVIE INC. | $852.28 | 12/31/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | Multicenter, Open-label Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder | No dispute reported | 06/30/2026 | 1202534055 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,339.00 | 11/25/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655308 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,284.00 | 11/25/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655310 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,339.00 | 11/25/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655312 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,284.00 | 11/25/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655314 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 11/25/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655316 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 11/25/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655318 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 11/25/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655320 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 11/25/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655322 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,339.00 | 11/25/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655324 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,284.00 | 11/25/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655326 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 11/25/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655328 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 11/25/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655330 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,339.00 | 11/25/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655332 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 11/25/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655334 |
| Principal investigator 1 | PFIZER INC. | $3,500.00 | 11/24/2025 | Non-covered Recipient Entity Elligo Health Research Inc | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228818509 |
| Principal investigator 1 | PFIZER INC. | $2,900.00 | 11/24/2025 | Non-covered Recipient Entity Elligo Health Research Inc | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228818555 |
| Principal investigator 1 | PFIZER INC. | $5,000.00 | 11/06/2025 | Non-covered Recipient Entity Elligo Health Research Inc | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228818549 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,801.35 | 10/22/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655258 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 10/02/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655286 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 10/02/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655288 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 10/02/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655290 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 10/02/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655292 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 10/02/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655294 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 10/02/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655296 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 10/02/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655298 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 10/02/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655300 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 10/02/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655302 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 10/02/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655304 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,999.00 | 10/02/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655306 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 09/03/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655256 |
| Principal investigator 1 | ABBVIE INC. | $3,712.50 | 08/06/2025 | Non-covered Recipient Entity MONTANO WELLNESS LLC | Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1202502873 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,200.00 | 07/28/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655270 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,200.00 | 07/28/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655272 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,200.00 | 07/28/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655274 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,284.00 | 07/28/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655278 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,284.00 | 07/28/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655280 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 07/25/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655254 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9,500.00 | 07/23/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655268 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 07/23/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655276 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 07/23/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655282 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $65.00 | 07/23/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655284 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 07/11/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655252 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,200.00 | 06/25/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655260 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,200.00 | 06/25/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655262 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 06/25/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655264 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 06/25/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655266 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,500.00 | 05/23/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655236 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $500.00 | 05/23/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655238 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 05/23/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655240 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $650.00 | 05/23/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655244 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,100.00 | 05/23/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655246 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 05/14/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655230 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,037.00 | 05/14/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655232 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 05/14/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655234 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 05/14/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655242 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.00 | 05/01/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655248 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.00 | 05/01/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655250 |
| Recipient | ABBVIE INC. | $998.58 | 04/10/2025 | Covered Recipient Physician | Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1202399986 |
| Recipient | ABBVIE INC. | $49.99 | 04/10/2025 | Covered Recipient Physician | Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1202399990 |
| Recipient | ABBVIE INC. | $24.99 | 04/10/2025 | Covered Recipient Physician | Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1202399994 |
| Recipient | ABBVIE INC. | $59.98 | 04/10/2025 | Covered Recipient Physician | Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1202399998 |
| Recipient | ABBVIE INC. | $24.99 | 04/10/2025 | Covered Recipient Physician | Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1202400002 |
| Recipient | ABBVIE INC. | $149.99 | 04/09/2025 | Covered Recipient Physician | Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1202399979 |
| Recipient | ABBVIE INC. | $303.97 | 04/09/2025 | Covered Recipient Physician | Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1202399983 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24,888.00 | 04/04/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655226 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $504.00 | 04/02/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655218 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $198.00 | 04/02/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655220 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 04/02/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655222 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,000.00 | 04/02/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655224 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 04/02/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655228 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.00 | 04/01/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655210 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.00 | 04/01/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655212 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.00 | 04/01/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655214 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.00 | 04/01/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655216 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.00 | 03/31/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655200 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.00 | 03/14/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655208 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,351.00 | 03/07/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655202 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,351.00 | 03/07/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655204 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,459.00 | 03/07/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655206 |
| Principal investigator 1 | PFIZER INC. | $750.00 | 03/06/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228821877 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.00 | 03/01/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655188 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.00 | 03/01/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655190 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.00 | 03/01/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655192 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.00 | 03/01/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655194 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.00 | 02/28/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655198 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $198.00 | 02/24/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655178 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,778.00 | 02/19/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655166 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,778.00 | 02/19/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655168 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,778.00 | 02/19/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655170 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,940.00 | 02/19/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655172 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,890.00 | 02/19/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655174 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,890.00 | 02/19/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655176 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $264.55 | 02/10/2025 | Non-covered Recipient Entity CT Clinical Research | A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia | No dispute reported | 06/30/2026 | 1220655336 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $495.00 | 02/03/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655162 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $478.00 | 02/03/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655164 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.00 | 02/01/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655180 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.00 | 02/01/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655182 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.00 | 02/01/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655184 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.00 | 02/01/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655186 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.00 | 01/31/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655196 |
| Principal investigator 1 | Eli Lilly and Company | $260.00 | 01/31/2025 | Non-covered Recipient Entity CONNECTICUT CLINICAL RESEARCH INSTITUTE LLC | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | No dispute reported | 06/30/2026 | 1187879663 |
| Principal investigator 1 | Eli Lilly and Company | $941.58 | 01/31/2025 | Non-covered Recipient Entity CONNECTICUT CLINICAL RESEARCH INSTITUTE LLC | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1187880139 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,850.00 | 01/29/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC DBA PREFERRED RESEARCH PARTNERS INC | AN OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 1242329851 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,625.00 | 01/29/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC DBA PREFERRED RESEARCH PARTNERS INC | AN OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER | No dispute reported | 06/30/2026 | 1242329853 |
| Principal investigator 1 | PFIZER INC. | $6,312.18 | 01/16/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228821883 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,108.00 | 01/15/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655130 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,037.00 | 01/15/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655132 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,108.00 | 01/15/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655134 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,037.00 | 01/15/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655136 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,351.00 | 01/15/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655138 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,459.00 | 01/15/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655140 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,351.00 | 01/15/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655142 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,459.00 | 01/15/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655144 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,029.00 | 01/15/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655146 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,940.00 | 01/15/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655148 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,029.00 | 01/15/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655150 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $378.00 | 01/15/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655152 |
| Principal investigator 1 | ABBVIE INC. | $850.00 | 01/07/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder or Bipolar 1 Disorder in Real World Setting | No dispute reported | 06/30/2026 | 1202436885 |
| Principal investigator 1 | Eli Lilly and Company | $51,292.00 | 01/06/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1187879909 |
| Principal investigator 1 | Eli Lilly and Company | $22,167.00 | 01/06/2025 | Non-covered Recipient Entity ELLIGO HEALTH RESEARCH INC | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | No dispute reported | 06/30/2026 | 1187879913 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.00 | 01/01/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655154 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.00 | 01/01/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655156 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.00 | 01/01/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655158 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.00 | 01/01/2025 | Non-covered Recipient Entity CT Clinical Research | A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD | No dispute reported | 06/30/2026 | 1220655160 |